My lab group investigates the molecular and cellular basis of Parkinson’s disease and related disorders. We use animal models and patient samples to identify molecular targets for patient stratification, fluid biomarkers and novel therapies. We believe that our research may contribute to understanding the aetiology of Parkinson´s disease and related disorders and ultimately hope to find a breakthrough therapeutic process that could slow down disease progression. We also hope that our neuropharmacology efforts will improve therapies for both motor and non-motor aspects, such as dementia assicoated with Parkinson´s disease. I am also leading a laboratory at the Karolinska Institute, where I am member of the Nobel assembly awarding the annual Nobel Prize in Physiology or Medicine.

Please see my Research Staff Profile for more detail

Key publications:

• He et al., 2023. Prosaposin maintains lipid homeostasis in dopamine neurons and counteracts experimental parkinsonism in rodents. Nature Commun.
• Chaudhuri et al., 2023. The noradrenergic subtype of Parkinson disease: from animal models to clinical practice. Nature Rev Neurol. 
• Paslawski et al., 2023. Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease. Transl Neurodegener.

View all publications

Key collaborators:

• Professor Dag Aarsland, King's College London
• Professor Ray Chaudhuri, King's College London
• Dr Diana Cash, King's College London
• Dr Frank Hirth, King's College London
• Dr Richard Killick, King's College London